    Lauren Riker | Pacira Pharmaceuticals, Inc. | ZoomInfo.com





RIKER, WILLIAM JR & LAUREN BULLARO New Jersey Property Records





WILLIAM RIKER New Jersey Property Information









 



Home
Search by owner
Complete List
Most Expensive
Contact Us
Random Property...










Owner Name: RIKER, WILLIAM JR & LAUREN BULLARO

Street Address: 224 S IRVING STREET City State: RIDGEWOOD NJ Zip Code: 07450 County: ocean County District: TOMS RIVER TWP Block: 01091 A numerical identification representing a tax map block number as it appears on the tax list. The block is nine characters, up to a five character block number and a four character block suffix.  Lot: 00018 A numerical identification representing a tax map lot number as it appears on the tax list. The lot is nine characters, up to a five character lot number and a four character lot suffix. Land Value: 185800 The assessed value of the site.  Improvement Value: 9100 The assessed value of the all improvements to the site.  Net Value: 194900 The value of the land plus the improvement value minus limited exemptions. Prior Year Net Value: 471600 Prior Year Net Value Current Year Tax: 0 Current Year Tax Last Year Tax: 7456 This field indicates the prior year net amount of tax. The decimal point is assumed. 
(This field is for towns that bill on a calendar year only.  Deduction Amount: 0 Lists the total dollar amount of deductions on the parcel. Deed Date: 2008-03-31 This is the date of deed for the sale of a property Sale Assessment: 123600 This field is for the assessment of the property at the time of the sale. Sale Price: 430000 This field shows the sales price indicated on the deed. The number one (1) indicates a nominal consideration sale.  Transaction Date: 2013-03-20 Indicates the last date a change was made to a particular block and lot. Transaction Update No.: 2318 The number of the accepted transaction listing for the last change to a particular block and lot.  Property Class: Residential An alpha-numeric field which identifies real property by use.  Property Location: 41 EAST COLONY ROAD This is the actual street address of the parcel.  Building Description: 1F         1028 Codes describe the physical characteristics of the property. The information should be listed in the 
following order: stories, exterior structural material, style, number of stalls and type of garage.  Land Description: 45X38 This alpha-numeric field accepts the size of the parcel in square feet, acres or actual dimensions.  Calculated Acreage: 0.0393 Lists the size of the parcel in acres. This field is automatically calculated from the land description field. Zoning: 40A This alpha-numeric field describes the zoning designations of the parcel.  Tax Map Page Number: 101 Lists the page on which the parcel can be found on the district tax maps.  Number Of Owners: 0 This field represents the number of owners of a property where a property tax deduction exists.  Bank Code: 00000 A numeric code indicating the name of the lending institution holding a mortgage on the parcel.  Deed Book: 13971 Indicates the book number where the current deed is filed.  Deed Page: 00110 Indicates the page number where the current deed is filed.  Sales Price Code: Actual This indicates how a sale was investigated for sales ratio purposes. 
A=Actual, F=Field, Q=Questionnaire 
 School Tax Overage: 0 School Tax Overage Percent Owned Code: 100% 1=10%, 2=20%, 3=30%, blank=100%.  Exempt Property List Own: 00 A numeric code identifying owner, purpose and specific use. This field is only mandatory for exempt 
property.  Exempt Property List Use: 00 Exempt Property List Use Exempt Property List Desc.: 000 Exempt Property List Description Building Class Code: 16 The building class from the appraisal manual for New Jersey assessors describing the quality of a property.  Year Constructed: 1948 This field indicates the year the building was constructed.  Special Tax Code 1: F01 Special Tax Code 1: F-Fire Special Tax Code 2: H93 Special Tax Code 2: G-Garbage 
 Special Tax Code 3: H84 Special Tax Code 3: L-Light Exemption Amt. 1: 0 Exemption Amount 1 Exemption Amt. 2: 0 Exemption Amount 2 Exemption Amt. 3: 0 Exemption Amount 3 Exemption Amt. 4: 0 Exemption Amount 4 Senior Citizens Count: 0 Senior Citizens Count (S) - $250 
 Veterans Count: 0 Veterans Count (V) - $250  Widows Count: 0 Widows Count (W) - $250 
 Surviving Spouse Count: 0 Surviving Spouse Count (R) - $250  Disabled Count: 0 Disabled Count (D) - $250  User Field 1: BBCB User Field 1 - This field contains various types of data User Field 2: WD 1 User Field 2 - This field contains various types of data Old Property ID: 01091   D00018 This field is populated with old block and lot designations upon the execution of a property 
identification change.  Rebate Response Flg: N Rebate Response Flag -N=No tenant rebate required, Y=tenant rebate notice is required 
 Rebate Base Year: 2012 This field indicates the base year for tenant rebate purposes. 
 Rebate Base Year Tax: 7456 This field indicates the taxes that were paid in the tenant rebate base year.  Rebate Base Year Net Value: 471600 This field indicates the net assessment of the property in the tenant rebate base year.  Non Municipal Half 1: 1535.1 This field indicates the net amount of non-municipal taxes for the first half of the current tax year. Non Municipal Half 2: 2914.29 This field indicates the net amount of non-municipal taxes for the second half of the current tax year.  Municipal Half 1: 521.97 This field indicates the net amount of municipal taxes for the first half of the current tax year. Municipal Half 2: 796.16 This field indicates the net amount of municipal taxes for the second half of the current tax year.  Non Municipal Half 3: 1593.6 Non Municipal Half 3 - This field is rarely used. Municipal Half 3: 448.49 Municipal Half 3 - This field is rarely used. 
 Estimated Quarter3 Tax: 1021.05 This field indicates the third quarter bill is based on a percentage of last yearâs taxes before the tax rates 
have been determined.  Statement Of State Aid Amt.: 0 Statement Of State Aid Amount Court Records Search: WILLIAM RIKERClick to run a court records search for WILLIAM RIKER now If your content is displayed on this page and you would like it removed for any reason, you may opt-out at any time by submitting a opt-out request

View Nearby Properties 

ZAEPFEL, KENNETH R1 SADORE LN APT #4A
	
      

TESTA, MICHAEL & JOSEPHINE M TRUST18 FRANCINE PLACE
	
      

CORRAO, JACQUELINE139 WINDING CREEK
	
      

LB LIMITED LLC139 WINDING CREEK
	
      

MURRAY, PATRICK & SUSAN2 KELLY COURT
	
      

POCHINSKI LTD LIABILITY COMPANYPO BOX 548
	
      

CAPOBIANCO, JASMINE3500 CHIPMAN ROAD
	
      

MANNINO, RONALD & SUZANNE564 MILLER COURT
	
      

SAVO, WILLIAM & KATHLEENP.O. BOX 6495
	
      

  DISCLAIMER: By using this site, you certify that you will use any information obtained for lawfully acceptable purposes.  Information contained herein is derived from records that may have errors and/or not always be accurate or complete. Data is sometimes entered poorly, processed incorrectly and may not be free from defect. This system should not be relied upon as definitively accurate. Before relying on any data this system supplies, it should be independently verified. This information is not to be used for any purpose described in the fair credit reporting act (FCRA). All searches are subject to legal restrictions, terms of use, and applicable law. All of this information is the representation of the management of the entities providing us this data. All content provided is deemed to be in the public domain. 





NAVIGATION


Home
Search by owner
Complete List
Most Expensive
Contact Us
Random Property...





© Copyright 2015 records.estate.PRIVACY POLICY







Lauren Bullaro Riker - Ridgewood, NJ | Intelius



























Sign In



We found Lauren Bullaro Riker in Ridgewood, NJ


Lauren Bullaro Riker

                                                                        Intelius found that Lauren Bullaro Riker  from Ridgewood, NJ.  We have connected them to
                4 addresses,
                1 phone,
                and 1 relative or associate.
         






Get Report Now

Lauren Has Lived In

Ridgewood, NJ
New York, NY
Frisco, TX

Lauren's Relatives

William Riker







Lauren Bullaro Riker



Professional Status
KPMG LLP



Get Report Now










Want to know more about Lauren? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Lauren, or use our people search engine to find others.
Get Background Check on Lauren Bullaro Riker
Get a Criminal Check on Lauren Bullaro Riker
Get a Public Record Report on Lauren Bullaro Riker
Get a People Search Report on Lauren Bullaro Riker


Lauren Bullaro Riker's Contact Information
Known Cities Lived In
Find out where Lauren Bullaro Riker has lived as well as Lauren Bullaro Riker's phone numbers and email addresses.




Lauren Bullaro Riker Has Lived in 3 States
New Jersey Address for Lauren Bullaro Riker


224 S I***** S* 

Ridgewood, NJ


Has Lived In

Ridgewood, NJ
New York, NY


Get Full Address Report










Phone Numbers Associated with Lauren Bullaro Riker

(416) ***-****


Get Full Phone Report



Email Addresses Associated with Lauren Bullaro Riker

l*********r@***.com


Get Email Report




Lauren Bullaro Riker's Education Information
Known Schools Attended
Learn about Lauren Bullaro Riker's academic history.  Find out which schools Lauren Bullaro Riker attended, the dates attended as well as the degrees Lauren Bullaro Riker received.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Lauren Bullaro Riker Has Attended 2 Schools
Columbia Business School 
Boston College                              Lauren Bullaro Riker has a B.S. in Accounting               


Lauren Bullaro Riker's Professional Information
Information regarding Lauren Bullaro Riker's professional history.  Find out previous places Lauren Bullaro Riker has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Lauren Bullaro Riker Has Worked at 5 Places
Company: KPMG LLP
               
Company: Pacira Pharmaceuticals , Inc.
               Title: Executive Director, Accounting and Financial Reporting
Lauren Bullaro Riker's Experience
Title: 
               Company: KPMG LLP
Job Details
               KPMG LLP, an Audit, Tax and Advisory firm (kpmg.ca) and a Canadian limited liability partnership established under the laws of Ontario, is the Canadian member firm of KPMG International Cooperative ("KPMG International"). KPMG member firms around the world have 145,000 professionals, in 152 countries. The independent member firms of the KPMG network are affiliated with KPMG International, a Swiss entity. Each KPMG firm is a legally distinct and separate entity, and describes itself as such. Follow @KPMG_Canada for more facts from KPMG's 2012 Canadian Manufacturing Outlook.
Title: Executive Director, Accounting and Financial Reporting
               Company: Pacira Pharmaceuticals , Inc.
Job Details
               Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients.
Additional Professional Information on Lauren Bullaro Riker

 See Lauren Bullaro Riker's LinkedIn Profile



Lauren Bullaro Riker's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Lauren Bullaro Riker


Lauren Bullaro Riker's known Social Networks And Potential Email Matches

Find all of Lauren Bullaro Riker's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Lauren Riker
Username Matches

                  LaurenRiker
                  RikerLauren
                  Lauren.Riker
                  Riker.Lauren
                  Lauren_Riker
                  Riker_Lauren
                  Lauren-Riker
                  Riker-Lauren
                  LRiker
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
L Riker







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.











Stock Screener - Yahoo FinanceHomeMailFlickrTumblrNewsSportsFinanceCelebrityAnswersGroupsMobileMoreYahooSearchSearch0U.S. Markets close in 6 hrs 3 minsS&P 5002,468.65-6.77 (-0.27%)Dow 3021,764.59-31.96 (-0.15%)Insider TransactionsDefault CriteriaInsider & Restricted Shareholder Transactions1-6 of 6 resultsResults were generated a few mins ago. Pricing data is updated frequently. Currency in USDSymbolDateSharesProceedsTransaction DetailsPCRX2017-06-133,000N/AAcquisition (Non Open Market) at $0.00 per share.PCRX2017-06-061,119$49,650.00Sale at $44.37 per share.PCRX2017-06-04601$26,035.00Sale at $43.32 per share.PCRX2016-06-143,125N/AAcquisition (Non Open Market) at $0.00 per share.PCRX2016-06-06617$30,000.00Sale at $47.90 - $47.90 per share.PCRX2016-06-05321$15,000.00Sale at $47.20 - $47.20 per share.Trump’s unwitting legacy could be universal health coverageYahoo FinanceHandsome Tungsten Wedding Bands $49.99Tungsten Fashions.comSponsoredU.S. economic growth picks up in second quarter, wages continue to lagReutersYahoo Small BusinessData DisclaimerHelpSuggestionsPrivacyAbout Our AdsTerms (Updated)








PCRX Lauren Bullaro Riker Insider Trades for Pacira Pharmaceuticals Inc.


































X

Tweet
 

Share this bulletin

Get news bulletins by email

Bulletin

Amazon tagged with 3.5% loss early Friday, pacing consumer-discretionary skid »
        




Investor Alert







New York Markets Close in:



Market Snapshot
Winners and Losers


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Pacira Pharmaceuticals Inc.

                  NASDAQ: PCRX
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Pacira Pharmaceuticals Inc.



Market open
 --Real time quotes
Jul 28, 2017, 9:57 a.m.


PCRX

/quotes/zigman/3627855/composite


$
39.80




Change

+0.25
+0.63%

Volume
Volume 118,118
Real time quotes








/quotes/zigman/3627855/composite
Previous close

$
			39.55
		


$
				39.80
			
Change

+0.25
+0.63%





Day low
Day high
$39.30
$40.40










52 week low
52 week high

            $29.95
        

            $58.95
        


















Insider Activity


Individual




Lauren Bullaro Riker



Ms. Lauren B. Riker is Vice President-Finance at Pacira Pharmaceuticals, Inc. She received her undergraduate degree from Boston College and an MBA from Columbia University.



Transactions


Date
Shares
Transaction
Value





06/14/2017
3,000


 
Award at $0 per share.


0


06/07/2017
1,119


 
Disposition at $44.37 per share.


49,651


06/05/2017
601


 
Disposition at $43.32 per share.


26,036


06/15/2016
3,125


 
Award at $0 per share.


0


06/07/2016
517


 
Disposition at $47.9 per share.


24,765


06/07/2016
100


 
Disposition at $47.9 per share.


4,790


06/06/2016
321


 
Disposition at $47.2 per share.


15,152


06/03/2015
3,750


 
Award at $0 per share.


0


03/16/2015
5,000


 
Disposition at $95.34 per share.


476,700


03/16/2015
5,000


 
Derivative/Non-derivative trans. at $10.34 per share.


51,700


03/14/2013
10,000


 
Disposition at $30 per share.


300,000


03/14/2013
10,000


 
Derivative/Non-derivative trans. at $10.34 per share.


103,400





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. David M. Stack 
Chairman & Chief Executive Officer




Mr. James S. Scibetta 
President




Mr. Charles A. Reinhart 
Chief Financial Officer




Dr. James B. Jones 
Chief Medical Officer & Senior Vice President




Dr. Vladimir  Kharitonov 
Vice President-Research & Development




Ms. Kristen Marie Williams 
Secretary & Chief Administrative Officer




Dr. Richard E. Scranton 
Vice President-Medical Health Sciences




Dr. Scott N. Braunstein 
Senior VP-Strategy & Corporate Development




Ms. Lauren Bullaro Riker 
Vice President-Finance




Dr. David  St. Peter 
Vice President-Advanced Solutions & Customer Care




Mr. Robert J. Weiland 
Chief Commercial Officer




Dr. Admir  Hadzic 
Director-New York School of Regional Anesthesia




Dr. Mark I. Froimson 
Director




Dr. Mark  Kronenfeld 
Director




Dr. Gary W. Pace 
Director




Mr. Thomas  Sluby 
Vice President-Sales




Ms. Susan  Mesco 
Head-Investor Relations




Mr. Richard  Kahr 
Vice President-Human Resources




Ms. Laura A. Brege 
Independent Director




Mr. Paul J. Hastings 
Lead Independent Director




Mr. Dennis L. Winger 
Independent Director




Dr. Yvonne L. Greenstreet 
Independent Director




Dr. Andreas  Wicki 
Independent Director




Dr. John P. Longenecker 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




9:57 AM EDT
July 28, 2017


/marketstate/country/us
New York

	Open


/marketstate/country/uk
London

	Open


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
9:55aThis type of investing could save the world — just don’t expect outperformance, too
9:54aThese tips can help advisers attract — and keep — high net worth clients
9:54aA menacing pattern has revealed itself in the stock market
9:53aTeaching people how to invest is one of the best marketing moves an adviser can make
9:45aA case for buying the freakin’ dip with Amazon, as the Mooch might now say
9:43aConsumer-discretionary sector slides as Amazon shares drop on results
9:42aShares of newspaper publisher McClatchy are up more than 2%
9:42a5 cities where you can buy a HUGE house for $100,000 or less
9:42aHow advisers can fight the ‘crisis of trust’ in financial services
9:38aBREAKINGStock market opens lower as Wall Street resumes tech selling
9:38aDestination Maternity plummets toward record low after merger deal terminated
9:38aThis is how Congress could craft a bipartisan health-care bill
9:36aMeet the ‘Hamilton’ actors who fly cross-country and play up to 18 roles in the hit show
9:34aTrump’s time—and political capital—is quickly running out
9:33aConsumer Discretionary Select Sector SPDR ETF falls 1% as Amazon.com sinks 4.1%
9:31aDow Jones Industrial Average opens less than 0.1% lower
9:31aS&P 500 opens down 0.2%
9:31aNasdaq Composite Index opens down 0.6%
9:30aU.S. stocks open lower as tech, consumer discretionary shares fall
9:24aDollar turns lower for the week following GDP report
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,765.63

-30.92
-0.14%





nasdaq

/quotes/zigman/12633936/realtime
6,358.40

-23.78
-0.37%





s&p 500

/quotes/zigman/3870025/realtime
2,468.62

-6.80
-0.27%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15

























































Riker Lauren Bullaro Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      Riker Lauren Bullaro
                    

•   PARSIPPANY, NJ
                      
How do I update this listing?




                                             Riker Lauren Bullaro is based out of Parsippany.    WhaleWisdom has at least 3 insider transactions (Form 3,4,5) in our database for Riker Lauren Bullaro. 
                                           














Summary
13D/G
Insider (Form 4)



   Create Email Alert
 




×
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from Riker Lauren Bullaro, enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




riker lauren bullaro


C/O PACIRA PHARMACEUTICALS, INC.

PARSIPPANY
NJ
                                                        
                                                    07054


                                                      Business Phone:
                                                      973-254-3560
SEC SIC CODE:2834-PHARMACEUTICAL PREPARATIONS







Recent SEC Filings




4 filed on 06/16/2017
4 filed on 06/09/2017
4 filed on 06/07/2017
4 filed on 12/09/2016
4 filed on 06/17/2016
4 filed on 06/08/2016
4 filed on 06/05/2015
4 filed on 03/18/2015
4 filed on 06/05/2014
4 filed on 03/18/2013
















Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...








Elevate your investments
Try it for free

















﻿






























Insider Selling: Pacira Pharmaceuticals, Inc. (PCRX) VP Sells 601 Shares of Stock - Stock Observer













































 















 



  
 
  





















Daily Ratings & News for Pacira Pharmaceuticals Inc.
        	Complete the form below to receive the latest headlines and analysts' recommendationsfor Pacira Pharmaceuticals Inc. with our free daily email newsletter:



 





Follow @StormInvestor







Recent Posts

Masimo Corporation (MASI) Receives New Coverage from Analysts at Stifel Nicolaus
Brokerages Set Mercantile Bank Corporation (NASDAQ:MBWM) Target Price at $33.50
Cott Corporation (NYSE:COT) Given Outperform Rating at Royal Bank Of Canada
J P Morgan Chase & Co (NYSE:JPM) Given Neutral Rating at Buckingham Research
Stryker Corporation (SYK) Price Target Raised to $158.00
Air Lease Corporation (NYSE:AL) Given Consensus Rating of “Buy” by Brokerages
Naples Global Advisors LLC Raises Position in GlaxoSmithKline PLC (GSK)
iShares S&P US Pref Stock Idx Fnd (PFF) Stake Maintained by A. D. Beadell Investment Counsel Inc.
Healthcare Trust of America, Inc. (NYSE:HTA) Stake Raised by A. D. Beadell Investment Counsel Inc.
Barton Investment Management Maintains Position in Teleflex Incorporated (NYSE:TFX)
Marston's PLC (MARS) Stock Rating Reaffirmed by Peel Hunt
HP Inc. (NYSE:HPQ) Director Margaret C. Whitman Sells 221,960 Shares
Tupperware Brands Corporation (NYSE:TUP) Updates Q3 Earnings Guidance
Gillon Beck Sells 37,500 Shares of Ormat Technologies, Inc. (ORA) Stock
Netflix, Inc. (NFLX) Receives Market Perform Rating from FBR & Co
Cohu, Inc. (COHU) Upgraded by Zacks Investment Research to Strong-Buy
ThyssenKrupp AG (FRA:TKA) Given a €27.00 Price Target at Independent Research GmbH
Timken Company (The) (NYSE:TKR) Rating Reiterated by Jefferies Group LLC
usell.com Inc. (OTCMKTS:USEL) Cut to “Strong Sell” at ValuEngine
Jean Coutu Group PJC Inc (TSE:PJC.A) Price Target Raised to C$21.00



 


Insider Selling: Pacira Pharmaceuticals, Inc. (PCRX) VP Sells 601 Shares of Stock

					Posted by George Bondi on Jul 7th, 2017 // No Comments 



Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) VP Lauren Bullaro Riker sold 601 shares of the firm’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $43.32, for a total value of $26,035.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 
Shares of Pacira Pharmaceuticals, Inc. (NASDAQ PCRX) opened at 49.75 on Friday. The firm’s market capitalization is $1.99 billion. Pacira Pharmaceuticals, Inc. has a 52-week low of $29.95 and a 52-week high of $58.95. The stock has a 50 day moving average price of $46.14 and a 200-day moving average price of $43.48. 


 Get Pacira Pharmaceuticals Inc. alerts:



Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, May 4th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. The firm had revenue of $69.30 million during the quarter, compared to analyst estimates of $70.30 million. Pacira Pharmaceuticals had a negative return on equity of 7.71% and a negative net margin of 19.26%. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.15 EPS. 




COPYRIGHT VIOLATION WARNING: This article was originally  reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.thestockobserver.com/2017/07/07/pacira-pharmaceuticals-inc-pcrx-vp-lauren-bullaro-riker-sells-601-shares-updated-updated-updated.html. 
A number of research analysts recently issued reports on PCRX shares. Canaccord Genuity  reiterated a “buy” rating and set a $60.00 price objective on shares of Pacira Pharmaceuticals in a report on Monday, May 15th. Royal Bank Of Canada  set a $58.00 price objective on Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, May 15th. HC Wainwright  set a $59.00 price objective on Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, March 16th. Zacks Investment Research downgraded Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 2nd. Finally, Barclays PLC  reiterated an “overweight” rating and set a $59.00 price objective (up from $54.00) on shares of Pacira Pharmaceuticals in a report on Tuesday, March 21st. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued  a buy rating to the company. The company  has a consensus rating of “Hold” and a consensus price target of $55.25.
Several institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC raised its position in  Pacira Pharmaceuticals by 1.6% in the fourth quarter. Renaissance Technologies LLC now owns 25,200 shares of the company’s stock valued at $814,000 after buying an additional 400 shares in the last quarter.  Avenir Corp raised its position in  Pacira Pharmaceuticals by 5.3% in the fourth quarter. Avenir Corp now owns 7,900 shares of the company’s stock valued at $255,000 after buying an additional 400 shares in the last quarter.  American International Group Inc. raised its position in  Pacira Pharmaceuticals by 5.3% in the first quarter. American International Group Inc. now owns 22,060 shares of the company’s stock valued at $1,006,000 after buying an additional 1,103 shares in the last quarter.  Benjamin F. Edwards & Company Inc. raised its position in  Pacira Pharmaceuticals by 85.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 2,491 shares of the company’s stock valued at $114,000 after buying an additional 1,149 shares in the last quarter.  Finally, Swiss National Bank raised its position in  Pacira Pharmaceuticals by 2.5% in the first quarter. Swiss National Bank now owns 61,300 shares of the company’s stock valued at $2,795,000 after buying an additional 1,500 shares in the last quarter. 
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.







Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



 



 























Latest News




Masimo Corporation  Receives New Coverage from Analysts at Stifel Nicolaus





Cott Corporation  Given Outperform Rating at Royal Bank Of Canada





Brokerages Set Mercantile Bank Corporation  Target Price at $33.50





J P Morgan Chase & Co  Given Neutral Rating at Buckingham Research





Stryker Corporation  Price Target Raised to $158.00





Air Lease Corporation  Given Consensus Rating of “Buy” by Brokerages






Leave a Reply

Click here to cancel reply.




Name  (Required) 



Mail (will not be published)  (Required) 



Website








 


 

 










































Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft



















Lauren Bullaro Riker - Pacira Pharmaceuticals Insider Transactions | TipRanks   





Go ProLogin / Sign Up Follow✓Get Real Time TransactionsInsider DetailsLauren Bullaro RikerPacira Pharmaceuticals (PCRX)VP FinanceRanked #27,906 out of 33,848 Insiders on TipRanksLauren Bullaro Riker's PerformanceProfitable Transactions2 out of 3 profitable transactionsAverage  Return-35.9%Average return per transactionEach transaction is measured over a 1 Year3 Months1 Month period, and compared to No BenchmarkS&P 500Sector.How are Insiders Ranked? Insider Holdings 100.0% Pacira Pharmaceuticals (PCRX)$271KSee the Top Stocks by Insiders > Insider RolesPacira Pharmaceuticals (PCRX): VP FinanceSee the Top 25 Corporate Insiders > Most Profitable Insider TradeStock: Pacira Pharmaceuticals (PCRX)Transaction Type: Informative SellDates: Mar 18, 2015 - Mar 18, 2016Gain: +51.2%See the Latest Stocks Traded by Insiders > Lauren Bullaro Riker's Trading Historybased on Form 4 Follow✓Get Real Time TransactionsCompany NameInsider PositionHolding ValueLast TransactionLast Transaction  AmountLast Transaction DatePCRXPacira PharmaceuticalsVP Finance$271,033Uninformative Buy$0Jun 16, 2017Success Rate on Stock2 out of 3 profitable transactions on PCRXAverage Profit on StockAverage return per transaction on PCRX -36.0% Track Record Showing:All TransactionsInformative TransactionsDateTransactionAmountNo. of SharesPrice per ShareProfitForm 4 Jun 16, 2017 Uninformative Buy $0 3,000 $42.3 N/A  Jun 09, 2017 Informative Sell $50K 1,119 $44.2 5.80%  Jun 07, 2017 Uninformative Sell $26K 601 $43.5 N/A Show MoreSee All Insider Trading from Today >You May Also LikeMeet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.Related LinksHow can I benefit from Insider Trading? >See the Top 25 Corporate Insiders >Go to Hot Stocks by Insiders >Find which stocks Insiders traded today >Become a TipRanks MemberGet the best Investing Tips & Hacks straight to your emailFree MembershipSubmitInsider Trading Daily NewsletterProfessional day-trading strategy based on predictive insider transactionsAnnual Return: +85.42%Learn More >Powered by
























     PCRX Company Profile & Executives - Pacira Pharmaceuticals Inc. - Wall Street Journal                                     DOW JONES, A NEWS CORP COMPANY         News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services.  DOW JONES  Barron's BigCharts DJX Dow Jones Newswires Factiva Financial News Mansion Global MarketWatch   Newsmart NewsPlus Private Markets Risk & Compliance WSJ.com WSJ Pro WSJ Conference WSJ Video    NEWS CORP  Big Decisions Business Spectator Checkout51 Harper Collins New York Post PropTiger REA   realtor.com Storyful The Australian The Sun The Times              DJIA ▲  21765.78 -0.14%        S&P 500 ▲  2468.62 -0.27%        Nasdaq ▲  6358.44 -0.37%        U.S. 10 Yr ▲  2/32 yield 2.304%        Crude Oil ▲  49.35 0.63%        Euro ▲  1.1728 0.44%                 Subscribe Now Sign In      The Wall Street Journal     U.S. Edition  U.S. Asia Europe India 中国 (China) 日本 (Japan)    July 28, 2017   Today's Paper     Sections    My Journal       Home   World   U.S.   Politics   Economy   Business   Tech   Markets   Opinion   Arts   Life   Real Estate   Today's Paper   SHOW ALL SECTIONS HIDE ALL SECTIONS     World Home   Africa Asia Canada China Europe Latin America Middle East   Economy   World Video     U.S. Home   Economy Law New York Politics   Real Time Economics Washington Wire   Journal Report U.S. Video What's News Podcast     Politics Home   Washington Wire   Politics Video WSJ/NBC News Poll     Economy Home   Real Time Economics   Economic Forecasting Survey Economy Video     Business Home   Management Tech/WSJ.D   Aerospace & Defense Autos & Transportation Commercial Real Estate Consumer Products Energy Entrepreneurship Financial Services Food & Services Health Care Hospitality Law Manufacturing Media & Marketing Natural Resources Retail   CFO Journal CIO Journal CMO Today Logistics Report Risk & Compliance   Heard on the Street   Business Video Journal Report Business Podcast     Tech Home   CIO Journal   Geoffrey Fowler Christopher Mims Joanna Stern Li Yuan   Billion Dollar Startup Club Tech Video Tech Podcast Startup Stock Trader     Markets Home   Bonds Commercial Real Estate Commodities & Futures Currencies Deals Financial Services Funds Stocks Your Money   Heard on the Street MoneyBeat Wealth Adviser Ahead of the Tape   CFO Journal Journal Report Market Data Markets Video Markets Podcast MoneyBeat Podcast Watching Your Wealth Podcast     Opinion Home   James Freeman William A. Galston Daniel Henninger Holman W. Jenkins William McGurn Peggy Noonan Mary Anastasia O'Grady Jason Riley Kimberley A. Strassel   Books Film Television Theater Art Masterpiece Series Music Dance Opera Exhibition Cultural Commentary   Editorials Commentary Letters to the Editor The Weekend Interview Potomac Watch Podcast Foreign Edition Podcast Opinion Video Notable & Quotable Best of the Web Newsletter Morning Editorial Report Newsletter     Arts Home   Books Film Television Theater Art Masterpiece Series   Arts Video WSJ. Magazine     Life Home   Careers Cars Food & Drink Health Ideas Real Estate Science Sports Style & Fashion Travel   Life Video WSJ. Magazine WSJ Puzzles The Future of Everything     Real Estate Home   Commercial Real Estate House of the Day Mansion   Real Estate Video      HIDE ALL SECTIONS      Aim higher, reach further.  Get the Wall Street Journal $12 for 12 weeks. Subscribe Now   Sign In   Reveal Navigation Options    Subscribe Sign In              Pacira Pharmaceuticals Inc. PCRX (U.S.: Nasdaq)      search    View All companies           REAL TIME 9:57 AM EDT 07/28/17     $39.80 USD     0.25 0.63%     Volume 48,267       Volume 48,267     65 Day Avg Vol 663,312     1 Day Range 39.30 - 40.05     52 Week Range 29.95 - 58.95 (12/02/16 - 03/01/17)          1 D 5 D 1 M 3 M YTD 1 Y 3 Y    $ %            Advanced Charting Compare     Compare to Benchmark:   DJIA   S&P 500   GLOBAL DOW   NASDAQ   Health Care/Life Sciences      Compare to    Add          Open  39.35   Prior Close  39.55 (07/26/17)     1 Day    PCRX 0.63%     DJIA -0.15%     S&P Mid Cap 400 -0.26%     Health Care/Life Sciences 0.00%                             Overview Profile Key People     Overview Profile Financials Income Statement Balance Sheet Cash Flow Research & Ratings Historical Prices Options Advanced Charting              Lauren Bullaro Riker, 37 Vice President-Finance, Pacira Pharmaceuticals, Inc. Ms. Lauren B. Riker is Vice President-Finance at Pacira Pharmaceuticals, Inc. She received her undergraduate degree from Boston College and an MBA from Columbia University.          News Pacira Pharmaceuticals Inc.PCRX   Significant News Only       07/26/17 Press Release   Pacira Announces Publication of Phase 4 Study of EXPAREL in Patients Undergoing Total Knee Replacement in The Journal of Arthroplasty   Press Release     07/25/17 Press Release   Pacira Pharmaceuticals Announces Timing for Second Quarter 2017 Financial Results Webcast and Conference Call   Press Release     07/25/17 Press Release   Pacira Announces Topline Phase 3 Results for EXPAREL(R) as a Single-dose Nerve Block   Press Release     06/29/17 Dow Jones Newswires   Pacira Pharmaceuticals Files 8K - Exits Or Disposals   Dow Jones Newswires     06/29/17 Dow Jones Newswires   Pacira Pharmaceuticals Files 8K - Material Impairments   Dow Jones Newswires     06/15/17 Dow Jones Newswires   Pacira Pharmaceuticals Files 8K - Changes Exec Mgmt   Dow Jones Newswires     06/15/17 Press Release   Pacira Pharmaceuticals Appoints Mark I. Froimson, M.D., to Board of Directors   Press Release     06/14/17 Press Release   Pacira Pharmaceuticals to Present at the JMP Securities Life Sciences Conference   Press Release     06/12/17 Press Release   Generic Drugs Stock Performance Review -- Ironwood Pharma, Medicines Co., Supernus Pharma, and Pacira Pharma   Press Release     06/01/17 Press Release   Pacira Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference   Press Release     05/23/17 Dow Jones Newswires   Pacira Pharmaceuticals Files 8K - Changes Exec Mgmt   Dow Jones Newswires     05/23/17 Press Release   Pacira Pharmaceuticals Announces Resignation of James Scibetta   Press Release     05/10/17 Press Release   Pacira Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference   Press Release     05/04/17 Press Release   Pacira Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results   Press Release     05/04/17 Press Release   ( PCRX ) Investor Network: Pacira Pharmaceuticals, Inc. to Host Earnings Call   Press Release     05/03/17 Press Release   New Research Shows Vast Majority of Oral Surgery Patients Would Choose Non-opioid Medication to Treat Postsurgical Pain if Given the Option   Press Release     05/01/17 Press Release   How These Generic Drugs Stocks are Faring? -- Medicines Co., Ironwood Pharma, Pacira Pharma, and Supernus Pharma   Press Release     02/02/17 MarketWatch.com   Fund that almost tripled the S&P 500’s gain last year is now big on health-care stocks   MarketWatch.com     10/01/15 Barron's   20 High-Quality Stocks On Goldman Sachs’ Buy List   Barron's     load more                All Company Executives Pacira Pharmaceuticals Inc.       David M. Stack, 65 Chairman & Chief Executive Officer     James S. Scibetta, 53 President     Charles A. Reinhart, 56 Chief Financial Officer     James B. Jones Chief Medical Officer & Senior Vice President     Vladimir Kharitonov Vice President-Research & Development     Kristen Marie Williams Secretary & Chief Administrative Officer     Richard E. Scranton Vice President-Medical Health Sciences     Scott N. Braunstein, 52 Senior VP-Strategy & Corporate Development     Lauren Bullaro Riker, 38 Vice President-Finance     David St. Peter Vice President-Advanced Solutions & Customer Care     Robert J. Weiland Chief Commercial Officer     Admir Hadzic Director-New York School of Regional Anesthesia     Mark I. Froimson, 57 Director     Mark Kronenfeld, 62 Director     Gary W. Pace, 69 Director     Thomas Sluby Vice President-Sales     Susan Mesco Head-Investor Relations     Richard Kahr Vice President-Human Resources     Laura A. Brege, 58 Independent Director     Paul J. Hastings, 57 Lead Independent Director     Dennis L. Winger, 69 Independent Director     Yvonne L. Greenstreet, 54 Independent Director     Andreas Wicki, 59 Independent Director     John P. Longenecker, 57 Independent Director      expand          Advertisement                 Notes & Data Providers   Real-time U.S. stock quotes reflect trades reported through Nasdaq only. International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times. Quote data, except U.S. stocks, provided by SIX Financial Information. Data is provided "as is" for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.  All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright  © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Bond quotes are updated in real-time. Source: Tullett Prebon. Currency quotes are updated in real-time. Source: Tullet Prebon. Fundamental company data and analyst estimates provided by FactSet. Copyright  FactSet Research Systems Inc. All rights reserved.        Advertisement                